Sientra’s “Stand-By” Series C Shows How To Eliminate Late-Stage Risk

Breast-implant start-up Sientra recently raised a $65 million Series C round at a time when venture capital for medtech is scarce, particularly for mid-stage companies pushing toward important milestones. Using a new kind of “stand-by” financing, it was ready to hit the ground running upon the recent FDA approval of its breast implants.

In this era of economic uncertainty, more and more venture capitalists are looking to minimize the risk of investing. This climate of caution is driving early-stage investors to invest in later-stage companies where the travel time to regulatory approval and commercialization is shortened by years. But even investing in late-stage companies with big ticket clinical and regulatory costs comes with risk ( well, in most cases anyway. The investors in Sientra Inc.’s $65 million Series C round managed to all but eliminate the risks associated with investing in a company awaiting approval from the Food and Drug Administration.

Abingworth Management Inc. led the financing, and all of the company’s inside investors returned, including Clarus Ventures and OrbiMed Advisors....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

Execs On The Move: July 7–11, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.